Loading stock data…
Celcuity Inc (CELC)
$93.02-2.68 (-2.80%)
Market ClosedLast close Sep 8
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Celcuity Inc. in the Healthcare sector is trading at $93.02 with a market capitalization of $4.3B. Wall Street consensus targets $161.09 (11 analysts), implying a +73.2% move over the next 12 months. The stock is currently 38% below its 52-week high of $151.02, remaining 12.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +73.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$50.51M↓ | -$49.20M↓ | -$42.85M↑ | -$44.01M↓ | -$36.13M |
| Net Income | -$52.84M↓ | -$50.97M↓ | -$43.80M↑ | -$45.27M↓ | -$37.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.25B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-360.37%
Volume
Today's trading volume
940,412
Recent News
Celcuity (CELC): Landmark Approval Collides With A Costly Launch
On August 13, Celcuity (NASDAQ:CELC) walked investors through a quarter unlike any in the company’s history. The clinical-stage biotech is no longer just clinical: its breast cancer drug Revtopik won FDA approval on July 14, and the call was built around how the company plans to turn that approval into an actual business. The tone […]
Celcuity (CELC) Q2 2026 Earnings Call Transcript
Revtopik launch underway with 80 oncology specialists supporting expansion into first-line treatment.
Is Celcuity (CELC) A Bargain As Losses Widen Ahead Of Its First Launch?
Celcuity (CELC) drew fresh attention after reporting second quarter 2026 results that showed a wider net loss as the company ramps up spending ahead of its first commercial oncology launch. See our latest analysis for Celcuity. Celcuity’s latest earnings report and recent FDA approval news have come after a sharp pullback, with the 90 day share price return down 30.4%, even as the 1 year total shareholder return sits at 77.6%. This suggests earlier strong gains are now cooling as investors...
How Investors May Respond To Celcuity (CELC) Winning FDA Nod For Revtopik Amid Wider Quarterly Loss
In the second quarter of 2026, Celcuity Inc. reported a wider net loss of US$78.86 million and basic loss per share of US$1.44, even as it prepared for the commercial launch of its newly FDA‑approved breast cancer therapy Revtopik (also referred to as REVTORPYK). The FDA approval of Revtopik for HR‑positive, HER2‑negative advanced breast cancer, combined with its upgrade to Category 1 preferred status in NCCN guidelines and strong VICTORIA‑1 efficacy data, marks a key turning point as...
Celcuity Inc. Q2 2026 Earnings Call Summary
Moby summary of Celcuity Inc.'s Q2 2026 earnings call